Generalized pustular psoriasis is a severe, chronic inflammatory skin condition characterized by widespread pustular eruptions and systemic inflammation. Unlike common plaque psoriasis, the disease carries significant risk of serious complications and increased mortality. Imsidolimab works by inhibiting IL-36 receptor signaling, effectively addressing the receptor antagonist deficiency typically found in patients suffering from the condition.
Vanda Pharmaceuticals Secures EU Orphan Status for Imsidolimab
The European Commission has granted orphan medicinal product designation to imsidolimab, a treatment for generalized pustular psoriasis, marking a significant regulatory milestone. This decision follows positive recommendations from the European Medicines Agency and aligns the drug’s status in the European Union with existing approvals in the United States and Japan.
This designation provides Vanda Pharmaceuticals with several regulatory advantages, including protocol assistance, reduced fees, and future market exclusivity within the European Union. Dr. Mihael H. Polymeropoulos, President and CEO of Vanda, noted that the move strengthens the company's global strategy to provide new therapeutic options to patients. While the drug gains traction in international markets, the company continues to await a final decision on its Biologics License Application from the U.S. Food and Drug Administration, which is currently slated for review by December 12, 2026.
Comments (0)
No comments yet. Be the first!